LivaNova PLC (NASDAQ:LIVN) Receives $65.63 Average Price Target from Analysts

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $69.3750.

LIVN has been the topic of a number of recent research reports. The Goldman Sachs Group restated a “neutral” rating and set a $66.00 price objective on shares of LivaNova in a research note on Friday. Mizuho increased their target price on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. KeyCorp started coverage on LivaNova in a research report on Friday, December 19th. They issued an “overweight” rating and a $81.00 price target on the stock. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Finally, Robert W. Baird set a $75.00 price objective on shares of LivaNova in a research note on Tuesday, December 16th.

LivaNova Stock Down 0.8%

Shares of LIVN opened at $64.41 on Wednesday. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. LivaNova has a 12 month low of $32.48 and a 12 month high of $65.57. The firm’s 50 day moving average is $60.10 and its 200-day moving average is $54.02. The stock has a market capitalization of $3.52 billion, a PE ratio of -16.10 and a beta of 0.97.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in LIVN. EP Wealth Advisors LLC bought a new stake in LivaNova during the first quarter worth $293,000. Amundi raised its holdings in shares of LivaNova by 7.2% during the 1st quarter. Amundi now owns 196,435 shares of the company’s stock worth $7,362,000 after buying an additional 13,142 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of LivaNova by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock worth $1,394,000 after buying an additional 1,360 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its stake in LivaNova by 8.3% in the first quarter. Dynamic Technology Lab Private Ltd now owns 16,869 shares of the company’s stock valued at $663,000 after buying an additional 1,286 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in LivaNova by 4.6% in the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after buying an additional 36,094 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.